Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA-638 is a biologic · 1 trial · 1 indication
Allergen inhalation test was performed at Screening, Day 14 and 35 to elicit airway responses similar to those that follow natural allergen exposure. FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. LAR was characterized by a fall in FEV1 of more than or equal to (\>=) 15 percent (%) at 3 to 7 hours post-allergen inhalation. Maximum drop in FEV1 relative to the pre-allergen baseline FEV1 between 3 to 7 hours at Screening was reported. Pre-allergen baseline FEV1 was performed in triplicate using spirometry and the best of the 3 values was selected.
Allergen inhalation test was performed at Screening, Day 14 and 35 to elicit airway responses similar to those that follow natural allergen exposure. FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. LAR was characterized by a fall in FEV1 of more than or equal to (\>=) 15 percent (%) at 3 to 7 hours post-allergen inhalation. Maximum drop in FEV1 relative to the pre-allergen baseline FEV1 between 3 to 7 hours on Day 14 was reported. Pre-allergen baseline FEV1 was performed in triplicate using spirometry and the best of the 3 values was selected.
Allergen inhalation test was performed at Screening, Day 14 and 35 to elicit airway responses similar to those that follow natural allergen exposure. FEV1 was the maximal volume of air exhaled in 1 second of a forced expiration from a position of full inspiration. LAR was characterized by a fall in FEV1 of more than or equal to (\>=) 15 percent (%) at 3 to 7 hours post-allergen inhalation. Maximum drop in FEV1 relative to the pre-allergen baseline FEV1 between 3 to 7 hours on Day 35 was reported. Pre-allergen baseline FEV1 was performed in triplicate using spirometry and the best of the 3 values was selected.
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| IMA-638 is a biologic | BIOLOGICAL | - |
Inclusion Criteria: Inclusion Criteria: * generally healthy, men and women with mild allergic asthma, aged 18 to 60 years * only asthma med is short-acting bronchodilator used not more than twice weekly * FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen inducti...
IMA-638 is an investigational biologic being studied for the treatment of asthma. It is a monoclonal antibody in Phase 2 clinical development. In a completed trial, it was evaluated for its effects on allergen-induced airway responses in subjects with mild atopic asthma.
IMA-638 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its effects on allergen-induced airway responses in patients with mild atopic asthma.
IMA-638 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this monoclonal antibody for asthma.
IMA-638 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
IMA-638 has been studied in one clinical trial, identified as NCT00410280. This Phase 2 study evaluated the effects of IMA-638 on allergen-induced airway responses in subjects with mild atopic asthma. The trial was completed and enrolled 30 participants in Canada.